Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, ...
24/7 Wall St. on MSN11h
Insider Buying Surges in February, Especially in These 6 StocksInsider buying surged in February. Warren Buffett continues to build a stake in a media stock, and IPOs tempted some insiders ...
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated ...
Notably, Metsera (MTSR, NC), an emerging player in the obesity market, saw its stock soar by 47% on its first trading day. Merger and acquisition (M&A) activities in the biotech space were few but ...
Notably, Metsera (MTSR, NC), an emerging player in the obesity market, saw its stock soar by 47% on its first trading day. Merger and acquisition (M&A) activities in the biotech space were few but ...
Metsera Inc is listed on the CBOE trading with ticker code MTSR.US. It has a market capitalisation of -, with approximately 0.00 shares in issue. Over the last year, Metsera Inc share price has ...
Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.
Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into ...
Over the last year, Metsera Inc share price has been traded in a range of 3.00, hitting a high of 28.60, and a low of 25.60. Metsera Inc is listed on the CBOE trading with ticker code MTSR.US.
Digital health firms in the city raised $4 billion in 2024, up 60% from the previous year, according to a report released ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback